EMA Authorised: Zykadia (ceritinib) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Zykadia (ceritinib) for the treatment of non-small cell lung cancer. The marketing authorization holder is Novartis Eur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Zykadia (ceritinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Novartis Europharm Limited. Decision date: 28/01/2026